Skip to main content

previous disabled Page of 2
and
  1. No Access

    Article

    Prediction of fragility fractures in men with prostate cancer under androgen deprivation therapy: the importance of a multidisciplinary approach using a mini-invasive diagnostic tool

    Bone fragility in men who are treated with androgen deprivation therapy (ADT) has a complex pathophysiology that differs from that of primary and post-menopausal osteoporosis. Fracture risk assessment based on...

    G. Mazziotti, A. G. Lania, Marta Laganà, Alfredo Berruti in Endocrine (2024)

  2. Article

    Open Access

    Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group

    Radioligand therapy (RLT) with lutetium (177Lu) oxodotreotide is an approved therapy in combination with somatostatin analogues (SSAs) for patients with advanced, well-differentiated G1–G2, gastro-entero-pancreat...

    Nicola Fazio, Massimo Falconi, Emanuela Foglia, Mirco Bartolomei in Advances in Therapy (2024)

  3. Article

    Open Access

    Terapia del carcinoma corticosurrenalico dopo fallimento del mitotane

    Il mitotane rappresenta l’unico farmaco approvato con specifica attività citotossica sulle cellule della corticale del surrene. Viene utilizzato nella terapia medica del carcinoma corticosurrenalico (ACC) nel ...

    Salvatore Grisanti, Valentina Cremaschi, Alfredo Berruti in L'Endocrinologo (2023)

  4. No Access

    Article

    The diagnostic and prognostic role of combined [18F]FDG and [68Ga]-DOTA-peptides PET/CT in primary pulmonary carcinoids: a multicentric experience

    In the present retrospective multicentric study, we combined [68Ga]-DOTA-peptides and [18F]FDG-PET/CT findings aiming to investigate their capability to differentiate typical (TC) and atypical pulmonary carcinoid...

    Domenico Albano, Francesco Dondi, Matteo Bauckneht in European Radiology (2023)

  5. Article

    Open Access

    Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question

    Whether or not androgen receptor (AR) axis could still be targetable in castration resistant prostate cancer (CRPC) patients with disease progression to next generation hormonal agents (NGHAs) is a controversi...

    Irene Caramella, Alberto Dalla Volta, Marco Bergamini, Deborah Cosentini in Endocrine (2022)

  6. Article

    Open Access

    Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen

    The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen. However, it is quite...

    Antonella Turla, Marta Laganà, Salvatore Grisanti, Andrea Abate in Endocrine (2022)

  7. Article

    Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1–2, 2021

    Alfredo Berruti, Massimo Terzolo, Sebastiano Filetti in Endocrine (2022)

  8. Article

    Open Access

    FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma

    FGF/FGFR signaling regulates embryogenesis, angiogenesis, tissue homeostasis and wound repair by modulating proliferation, differentiation, survival, migration and metabolism of target cells. Understandably, c...

    Mariangela Tamburello, Barbara Altieri, Iuliu Sbiera, Sandra Sigala in Endocrine (2022)

  9. Article

    Open Access

    Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?

    Pediatric and adult adrenocortical carcinomas differ in many respects but treatment is often similar in both age groups. The Journal of Clinical Oncology recently published the results of a risk-stratified single...

    Salvatore Grisanti, Deborah Cosentini, Marta Laganà, Antonella Turla in Endocrine (2021)

  10. Article

    Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy

    Deborah Cosentini, Salvatore Grisanti, Marta Laganà, Vittorio Domenico Ferrari in Endocrine (2021)

  11. Article

    Maintenance everolimus beyond progression in pancreatic NET to control insulinoma syndrome

    Valeria Tovazzi, Vittorio D. Ferrari, Alfredo Berruti in Endocrine (2021)

  12. No Access

    Chapter

    Cancer of the Thyroid

    Thyroid cancers are the most frequent endocrine neoplasms whose incidence is globally increasing. Thyroid carcinomas basically derived from follicular (papillary, follicular, anaplastic and poorly differentiat...

    Valerio Gristina, Nadia Barraco, Silvio Buscemi in Practical Medical Oncology Textbook (2021)

  13. No Access

    Chapter

    Cancer of the Adrenal Gland

    The embryology and physiology of the adrenal gland is complex, and two different tumors may arise according to whether the cell transformation occurs in the cortex or medulla. Most of these tumors are benign, ...

    Mélanie Claps, Deborah Cosentini, Elisa Roca in Practical Medical Oncology Textbook (2021)

  14. No Access

    Article

    Should everolimus be stopped after radiological progression in metastatic insulinoma? A “cons” point of view

    Insulinoma is a rare pancreatic neuroendocrine tumor (pNET) potentially associated with severe hypoglycaemic crisis. The great majority of these tumors are benign. In patients with metastatic malignant insulin...

    Valeria Tovazzi, Vittorio D. Ferrari, Alberto Dalla Volta, Francesca Consoli in Endocrine (2020)

  15. No Access

    Article

    Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

    Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarke...

    Alessandro Russo, Marco Russano, Tindara Franchina in Advances in Therapy (2020)

  16. No Access

    Article

    Antineoplastic activity of artemisinin in adrenocortical carcinoma

    Luigi Lorini, Salvatore Grisanti, Roberta Ambrosini, Deborah Cosentini in Endocrine (2019)

  17. No Access

    Article

    Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents

    Marcello Tucci, Elisa Roca, Laura Ferrari, Anna Pia, Alberto Dalla Volta in Endocrine (2019)

  18. No Access

    Article

    In vitro antitumor activity of progesterone in human adrenocortical carcinoma

    The management of patients with adrenocortical carcinoma (ACC) is challenging. As mitotane and chemotherapy show limited efficacy, there is an urgent need to develop therapeutic approaches. The aim of this stu...

    Martina Fragni, Chiara Fiorentini, Elisa Rossini, Simona Fisogni, Sara Vezzoli in Endocrine (2019)

  19. No Access

    Article

    Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma

    Mélanie Claps, Sara Cerri, Salvatore Grisanti, Barbara Lazzari in Endocrine (2018)

  20. No Access

    Article

    Palbociclib inhibits proliferation of human adrenocortical tumor cells

    Chiara Fiorentini, Martina Fragni, Guido A. M. Tiberio, Diego Galli in Endocrine (2018)

previous disabled Page of 2